• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Abilify (aripiprazole)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Abilify (aripiprazole)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Abilify (aripiprazole) is an orally administered drug approved in November 2002 for the treatment of schizophrenia. It is a dopamine partial agonist and a seratonin antagonist.

    Abilify oral tablets are available in 10mg, 15mg, 20mg, and 30mg doses. The 15mg strength is the recommended starting and effective dose.

    Clinical Results

    Four short-term, placebo-controlled clinical trials were conducted with Abilify in acute replapsed inpatients with schizophrenia. In three of the four trials, efficacy was measured by the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression Severity of Illness Score (CGI-S). In the three trials, Abilify was statistically superior to placebo using these measures.

    In the fourth trial, efficacy was measured by a responder analysis based on the CGI-S and the change in Brief Psychiatric Rating Scale (BPRS). Abilify was statistically superior to placebo based on the CGI-S, but not in the BPRS measure.

    Clinical efficacy was demonstrated by the 15mg, 20mg and 30mg doses in two trials each. Clinical efficacy was shown for the 10mg dose in one trial. No evidence of clinical superiority was shown by the higher doses compared to the lowest dose.

    Side Effects

    The following are some of the adverse events that were experienced in clinical trials by 2% or more of subjects receiving aripiprazole:

    • Headache
    • Anxiety
    • Nausea
    • Vomiting
    • Constipation
    • Insomnia
    • Lightheadedness
    • Somnolence (sleepiness)
    • Akathisia (condition of motor restlessness)

    No siginficant differences were found in incidence of discontinuation due to adverse events experienced by the aripiprazole group compared to the placebo group.

    Note: Neuroleptic malignant syndrome (NMS), a rare but sometimes fatal condition, has been associated with antipsychotic drugs, including Abilify. In addition, tardive dyskinesia (TD) has also been associated with antipsychotic drugs.

    Mechanism of Action

    Abilify is a dopamine partial agonist and a seratonin antagonist.

    Additional Information

    For additional information about Abilify, please visit product web site at www.abilify.com.

    Approval Date: 2002-11-01
    Company Name: Bristol-Myers Squibb, Otsuka America Pharmaceutical
    Back to Listings

    Upcoming Events

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing